A universal respiratory syncytial virus (RSV) immunization program using Sanofi’s Beyfortus (nirsevimab) was associated with ...
One bill in our legislative session that was getting a lot of attention, at least with respect to written testimony, is Senate Bill 1434, Relating to Universal Immunization Funding Program. This bill ...
Sanofi reported new real-world evidence showing that immunization with Beyfortus can significantly reduce RSV-related hospitalizations not only during an infant’s first RSV season but also into the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results